View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsPharmiva 将来の成長Future 基準チェック /06現在、 Pharmivaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長35.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Oct 13Pharmiva Applies for Delisting of its Shares from Nasdaq First North Growth MarketOn June 15, 2023, the shares in Pharmiva AB (publ) (‘Pharmiva’) were given observation status with reference to information that Pharmiva had entered into a letter of intent to merge with PEPTONIC medical AB (‘PEPTONIC’), according to which Pharmiva will be absorbed by PEPTONIC. On October 12, 2023, Pharmiva applied for delisting of its shares from Nasdaq First North Growth Market, conditional on the completion of the merger with PEPTONIC. The rules of Nasdaq First North Growth Market state that an issuer may be given observation status if the issuer has applied to have its financial instruments removed from Nasdaq First North Growth Market. With reference to the above, Nasdaq Stockholm AB decides to update the observation status for the shares in Pharmiva AB (publ)(PHARM, ISIN code SE0015530670, order book ID 219373).Reported Earnings • Aug 18Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr897.0k (down 23% from 2Q 2022). Net loss: kr6.05m (loss narrowed 19% from 2Q 2022).お知らせ • Jun 17PEPTONIC medical AB (publ) (NGM:PMED) signed a letter of intent to acquire Pharmiva AB (publ) (OM : PHARM) for SEK 15.2 million.PEPTONIC medical AB (publ) (NGM:PMED) signed a letter of intent to acquire Pharmiva AB (publ) (OM : PHARM) for SEK 15.2 million on June 15, 2023. In order to carry out the distribution as above, the Company's intention is, indicatively, that shareholders in Pharmiva shall receive [twelve (12)] shares in Peptonic for each one (1) share owned in Pharmiva in the form of merger consideration. However, the final merger consideration will be determined after the Companies have prepared and adopted a joint merger plan for the Merger. After completion of the transaction, Peptonic's holding is intended to amount to eighty-five (85) percent of the number of shares in New Peptonic. harmiva's holding is intended to amount to fifteen (15) percent of the number of shares in New Peptonic. The joining of the two companies is planned to be completed through a merger under Swedish company law. The completion of the Merger is conditional upon, inter alia, that the Boards of Directors of each company resolve to complete the Merger and that the Merger is approved by an extraordinary general meeting in Pharmiva. The final decision on the merger will be made after union negotiations have been completed. Mangold Fondkommission AB is acting as financial advisor in connection with the planned Merger. Eversheds Sutherland Advokatbyrå AB is legal advisor in connection with the planned Merger.お知らせ • Jun 16Pharmiva AB (publ) (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB (publ) (NGM:PMED).Pharmiva AB (publ) (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB (publ) (NGM:PMED) on June 15, 2023. According to the Takeover rules for certain trading platforms, which are administered by the Swedish Stock Market Self-Regulation Committee, the rules also apply in the event of mergers and merger-like processes.Reported Earnings • May 30First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr1.08m (up 154% from 1Q 2022). Net loss: kr5.33m (loss narrowed 14% from 1Q 2022).Reported Earnings • Feb 24Full year 2022 earnings released: kr2.88 loss per share (vs kr3.15 loss in FY 2021)Full year 2022 results: kr2.88 loss per share. Revenue: kr3.88m (up 66% from FY 2021). Net loss: kr23.7m (loss widened 14% from FY 2021).Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Ulf Blom was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 21Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr1.17m (up 79% from 2Q 2021). Net loss: kr7.44m (loss widened 66% from 2Q 2021). Over the next year, revenue is forecast to grow 149%, compared to a 88% growth forecast for the Pharmaceuticals industry in Sweden.Reported Earnings • Apr 16Full year 2021 earnings released: kr3.15 loss per share (vs kr3.78 loss in FY 2020)Full year 2021 results: kr3.15 loss per share. Net loss: kr20.8m (loss widened 48% from FY 2020). Over the next year, revenue is forecast to grow 12%, compared to a 98% growth forecast for the pharmaceuticals industry in Sweden.Reported Earnings • Nov 24Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: kr0.67 loss per share. Net loss: kr4.80m (flat on 3Q 2020). Revenue was in line with analyst estimates. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Pharmiva は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OM:PHARM - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20234-21-20-19N/A3/31/20235-23-24-22N/A12/31/20224-24-25-23N/A9/30/20223-23-24-22N/A6/30/20223-24-26-24N/A3/31/20222-21-25-23N/A12/31/20212-21-24-21N/A9/30/20212-19-22-19N/A6/30/20212-18-20-18N/A3/31/20211-16-14-13N/A12/31/20201-14-16-15N/A12/31/20192-1126N/A4/30/20195-4-18-13N/A4/30/20183-2N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PHARMの予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PHARMの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PHARMの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PHARMの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: PHARMの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PHARMの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/11/21 14:36終値2023/11/17 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmiva AB (publ) これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Niklas ElmhammerCarlsquare AB
お知らせ • Oct 13Pharmiva Applies for Delisting of its Shares from Nasdaq First North Growth MarketOn June 15, 2023, the shares in Pharmiva AB (publ) (‘Pharmiva’) were given observation status with reference to information that Pharmiva had entered into a letter of intent to merge with PEPTONIC medical AB (‘PEPTONIC’), according to which Pharmiva will be absorbed by PEPTONIC. On October 12, 2023, Pharmiva applied for delisting of its shares from Nasdaq First North Growth Market, conditional on the completion of the merger with PEPTONIC. The rules of Nasdaq First North Growth Market state that an issuer may be given observation status if the issuer has applied to have its financial instruments removed from Nasdaq First North Growth Market. With reference to the above, Nasdaq Stockholm AB decides to update the observation status for the shares in Pharmiva AB (publ)(PHARM, ISIN code SE0015530670, order book ID 219373).
Reported Earnings • Aug 18Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr897.0k (down 23% from 2Q 2022). Net loss: kr6.05m (loss narrowed 19% from 2Q 2022).
お知らせ • Jun 17PEPTONIC medical AB (publ) (NGM:PMED) signed a letter of intent to acquire Pharmiva AB (publ) (OM : PHARM) for SEK 15.2 million.PEPTONIC medical AB (publ) (NGM:PMED) signed a letter of intent to acquire Pharmiva AB (publ) (OM : PHARM) for SEK 15.2 million on June 15, 2023. In order to carry out the distribution as above, the Company's intention is, indicatively, that shareholders in Pharmiva shall receive [twelve (12)] shares in Peptonic for each one (1) share owned in Pharmiva in the form of merger consideration. However, the final merger consideration will be determined after the Companies have prepared and adopted a joint merger plan for the Merger. After completion of the transaction, Peptonic's holding is intended to amount to eighty-five (85) percent of the number of shares in New Peptonic. harmiva's holding is intended to amount to fifteen (15) percent of the number of shares in New Peptonic. The joining of the two companies is planned to be completed through a merger under Swedish company law. The completion of the Merger is conditional upon, inter alia, that the Boards of Directors of each company resolve to complete the Merger and that the Merger is approved by an extraordinary general meeting in Pharmiva. The final decision on the merger will be made after union negotiations have been completed. Mangold Fondkommission AB is acting as financial advisor in connection with the planned Merger. Eversheds Sutherland Advokatbyrå AB is legal advisor in connection with the planned Merger.
お知らせ • Jun 16Pharmiva AB (publ) (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB (publ) (NGM:PMED).Pharmiva AB (publ) (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB (publ) (NGM:PMED) on June 15, 2023. According to the Takeover rules for certain trading platforms, which are administered by the Swedish Stock Market Self-Regulation Committee, the rules also apply in the event of mergers and merger-like processes.
Reported Earnings • May 30First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr1.08m (up 154% from 1Q 2022). Net loss: kr5.33m (loss narrowed 14% from 1Q 2022).
Reported Earnings • Feb 24Full year 2022 earnings released: kr2.88 loss per share (vs kr3.15 loss in FY 2021)Full year 2022 results: kr2.88 loss per share. Revenue: kr3.88m (up 66% from FY 2021). Net loss: kr23.7m (loss widened 14% from FY 2021).
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Ulf Blom was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 21Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr1.17m (up 79% from 2Q 2021). Net loss: kr7.44m (loss widened 66% from 2Q 2021). Over the next year, revenue is forecast to grow 149%, compared to a 88% growth forecast for the Pharmaceuticals industry in Sweden.
Reported Earnings • Apr 16Full year 2021 earnings released: kr3.15 loss per share (vs kr3.78 loss in FY 2020)Full year 2021 results: kr3.15 loss per share. Net loss: kr20.8m (loss widened 48% from FY 2020). Over the next year, revenue is forecast to grow 12%, compared to a 98% growth forecast for the pharmaceuticals industry in Sweden.
Reported Earnings • Nov 24Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: kr0.67 loss per share. Net loss: kr4.80m (flat on 3Q 2020). Revenue was in line with analyst estimates.